Top Biopreservation Companies

Global Biopreservation Market size was valued at USD 3.59 Billion in 2024 and is poised to grow from USD 4.61 Billion in 2025 to USD 33.82 Billion by 2033, growing at a CAGR of 28.3% during the forecast period (2026–2033). 

Biopreservation market is capital and innovation extensive hence it is dominated by large multinational companies. There is a higher degree of collaboration between the government and private sector in terms of research and funding. Government regulations are also on the higher side in the market, and they vary for each geography. Hence, companies with wider regional outreach have a competitive edge.  'Thermo Fisher Scientific Inc. (United States) ', 'Merck KGaA (Germany) ', 'BioLife Solutions, Inc. (United States) ', 'STEMCELL Technologies (Canada) ', 'Helmer Scientific Inc. (United States) ', 'PrincetonCryo (United States) ', 'OPS Diagnostics (United States) ', 'ThermoGenesis Holdings, Inc. (United States) ', 'Avantor, Inc. (United States) ', 'Bio-Techne Corporation (United States) ', 'Exact Sciences Corporation (United States) ', 'Worthington Industries, Inc. (United States) ', 'Chart Industries, Inc. (United States) ', 'Azenta US, Inc. (United States) ', 'LabVantage Solutions, Inc. (United States) ', 'Qiagen N.V. (Netherlands) ', 'Taylor-Wharton Cryogenics LLC (United States) ', 'PHC Holdings Corporation (Japan) ', 'Panasonic Corporation (Japan) ', 'Lifeline Scientific, Inc. (United States) '

Reported chronic diseases cases are on the rise globally. In developed economies such as the US chronic disease was reported annually in more than 30% of the adult population while in developing economies such as India, chronic diseases were reported in more than 23% of the adult population. Chronic diseases have high requirement of diagnosis and other alternate therapies thus boosting the demand for biopreservation. 

Cell therapy and genetic engineering demand is expected to witness more than 30% CAGR during the forecast period. This is attracting investment from biomedical companies for research and development. Cell and gene therapy is transforming the diagnosis and treatment of critical patients and chronic diseases. Government spending on research centers focusing on gene therapy and regenerative treatment is also expected to grow. 

North America dominated the market and accounted for highest Biopreservation Market share in 2023, driven by flourishing healthcare sector and growing budget for pharmaceutical research. US accounts for the largest market for clinical trials of new drugs and is the powerhouse of drug discovery. The presence of research centers of large pharmaceutical companies and world class healthcare providers creates high demand for biopreservation of samples required in treatment and research. In addition, the number of cases of chronic disease is significantly high and acceptance of personalized medication using regenerative techniques is also significantly more mature in North America especially in the US.